These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 35945647)

  • 1. Targeted nanotherapy for kidney diseases: a comprehensive review.
    Sabiu G; Kasinath V; Jung S; Li X; Tsokos GC; Abdi R
    Nephrol Dial Transplant; 2023 May; 38(6):1385-1396. PubMed ID: 35945647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological principles underlying the kidney targeting of renal nanomedicines.
    Huang Y; Ning X; Ahrari S; Cai Q; Rajora N; Saxena R; Yu M; Zheng J
    Nat Rev Nephrol; 2024 Jun; 20(6):354-370. PubMed ID: 38409369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in kidney-targeted drug delivery systems.
    Chen Z; Peng H; Zhang C
    Int J Pharm; 2020 Sep; 587():119679. PubMed ID: 32717283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicines for renal disease: current status and future applications.
    Kamaly N; He JC; Ausiello DA; Farokhzad OC
    Nat Rev Nephrol; 2016 Dec; 12(12):738-753. PubMed ID: 27795549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines for kidney diseases.
    Williams RM; Jaimes EA; Heller DA
    Kidney Int; 2016 Oct; 90(4):740-5. PubMed ID: 27292222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for Renal Management: From Imaging to Treatment.
    Jiang D; Rosenkrans ZT; Ni D; Lin J; Huang P; Cai W
    Acc Chem Res; 2020 Sep; 53(9):1869-1880. PubMed ID: 32786331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions.
    Trac N; Ashraf A; Giblin J; Prakash S; Mitragotri S; Chung EJ
    ACS Nano; 2023 Apr; 17(7):6165-6177. PubMed ID: 36988207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advance cardiac nanomedicine by targeting the pathophysiological characteristics of heart failure.
    Lin C; Gao H; Ouyang L
    J Control Release; 2021 Sep; 337():494-504. PubMed ID: 34358590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules.
    Liu CP; Hu Y; Lin JC; Fu HL; Lim LY; Yuan ZX
    Med Res Rev; 2019 Mar; 39(2):561-578. PubMed ID: 30136283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarrier-based localized and effective treatment of renal disorders: currently employed targeting strategies.
    Ullah S; Burki S; Munir AB; Yousaf G; Shafique M
    Nanomedicine (Lond); 2024 Feb; 19(4):345-361. PubMed ID: 38293889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Application of Nanoparticles in Diagnosis and Treatment of Kidney Diseases.
    Paluszkiewicz P; Martuszewski A; Zaręba N; Wala K; Banasik M; Kepinska M
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.
    Maurya S; Srivastava R; Arfin S; Hawthorne S; Jha NK; Agrawal K; Raj S; Rathi B; Kumar A; Raj R; Agrawal S; Paiva-Santos AC; Malik AA; Dua K; Rana R; Ojha S; Jha SK; Sharma A; Kumar D; El-Zahaby SA; Nagar A
    Nanomedicine (Lond); 2022 Dec; 17(30):2245-2264. PubMed ID: 36975758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions.
    Huang Y; Wang J; Jiang K; Chung EJ
    J Control Release; 2021 Jun; 334():127-137. PubMed ID: 33892054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Drug Delivery Technologies and Targets for Renal Disease.
    Chade AR; Bidwell GL
    Hypertension; 2022 Sep; 79(9):1937-1948. PubMed ID: 35652363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines as cancer therapeutics: current status.
    Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
    Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of nanomedicines for neuron targeting.
    Garcia-Chica J; D Paraiso WK; Tanabe S; Serra D; Herrero L; Casals N; Garcia J; Ariza X; Quader S; Rodriguez-Rodriguez R
    Nanomedicine (Lond); 2020 Jul; 15(16):1617-1636. PubMed ID: 32618490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.